Results 21 to 30 of about 1,482,586 (339)
Small extracellular vesicle-mediated ITGB6 siRNA delivery downregulates the αVβ6 integrin and inhibits adhesion and migration of recipient prostate cancer cells
Cancer Biology & Therapy, 2022 The αVβ6 integrin, an epithelial-specific cell surface receptor absent in normal prostate and expressed during prostate cancer (PrCa) progression, is a therapeutic target in many cancers.Shiv Ram Krishn, Vaughn Garcia, Nicole M. Naranjo, Fabio Quaglia, Christopher D. Shields, Maisha A. Harris, Andrew V. Kossenkov, Qin Liu, Eva Corey, Dario C. Altieri, Lucia R. Languino +10 moredoaj +1 more sourceCoupling of alpha(1)-Adrenoceptors to ERK1/2 in the Human Prostate [PDF]
, 2011 Introduction: alpha(1)-Adrenoceptors are considered critical for the regulation of prostatic smooth muscle tone. However, previous studies suggested further alpha(1)-adrenoceptor functions besides contraction.Anglin IE, Boris Schlenker, Chang L, Chon JK, Christ GJ, Christian G. Stief, Christian Gratzke, Erdogru T, Frank Strittmatter, Glassman DT, Golomb E, Johanna Göttinger, Kanagawa K, Karl-Erik Andersson, Kyprianou N, Kyprianou N, Kyprianou N, Lucia MS, Luthin GR, Marinese D, Maroni PD, Martin Hennenberg, McCubrey JA, McVary KT, Michel MC, Oliver Reich, Petter Hedlund, Ricarda M. Bauer, Roehrborn CG, Roehrborn CG, Royuela M, Royuela M, Schilit S, Schwinn DA, Shimada K, Srinivasan D, Turkeri LN, Xiao L, Zhang H, Zhang Z +39 morecore +1 more sourceProstate sarcoma
IJU Case Reports, 2023 IntroductionThis report is intended to provide insight into the presentation, diagnosis, and treatment of prostatic sarcomas. A literature review is included to compare variables in demographics, histology, prognosis, and treatment strategies among previously reported incidences.Case presentationIn this case, we have a 72‐year‐old man who initially ...Nicholas T Ehat, Lisa Chuong, Jenna Dickman, Tom Deng, George Chang, Jonathan Hwang +5 moreopenaire +3 more sourcesTOP2A and EZH2 Provide Early Detection of an Aggressive Prostate Cancer Subgroup. [PDF]
, 2017 Purpose: Current clinical parameters do not stratify indolent from aggressive prostate cancer. Aggressive prostate cancer, defined by the progression from localized disease to metastasis, is responsible for the majority of prostate cancer–associated ...Alshalalfa, Mohammed,, Bowden, Michaela,, Brown, Myles,, Davicioni, Elai,, Den, Robert B.,, Ellis, Leigh,, Eng, Kevin H.,, Erho, Nicholas,, Feng, Felix Y.,, Galbo, Phillip,, Goodrich, David W.,, Gray, Kathryn P.,, Huang, Ying,, Jenkins, Robert B.,, Karnes, R. Jeffrey,, Ku, Sheng Yu,, Labbé, David P.,, Lund University., Rosario, Spencer,, Ross, Ashley E., Schaeffer, Edward M.,, Sjöström, Martin,, Spratt, Daniel E.,, Sweeney, Christopher J.,, Wadosky, Kristine M., +24 morecore +2 more sourcesTwo-year quality of life after robot-assisted radical prostatectomy according to pentafecta criteria and cancer of the prostate risk assessment (CAPRA-S)
Scientific Reports, 2022 The quality of life (QoL) of men with optimal outcomes after robot-assisted radical prostatectomy (RARP) is largely unexplored. Thus we assessed meaningful changes of QoL measured with the EORTC QLQ-C30 24 months after RARP according to postsurgical ...Theodoros Karagiotis, Jorn H. Witt, Thomas Jankowski, Mikolaj Mendrek, Christian Wagner, Andreas Schuette, Nikolaos Liakos, Pawel Rachubinski, Katarina Urbanova, Matthias Oelke, Mykyta Kachanov, Sami-Ramzi Leyh-Bannurah +11 moredoaj +1 more sourceProtocol for the P3BEP trial (ANZUP 1302): an international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours
BMC Cancer, 2018 Background Bleomycin, etoposide, and cisplatin (BEP) chemotherapy administered every 3 weeks for 4 cycles remains the standard first line treatment for patients with intermediate- and poor-risk metastatic germ cell tumours (GCTs).Nicola J. Lawrence, Howard Chan, Guy Toner, Martin R. Stockler, Andrew Martin, Sonia Yip, Nicole Wong, Annie Yeung, Danish Mazhar, Farzana Pashankar, Lindsay Frazier, Ray McDermott, Roderick Walker, Hsiang Tan, Ian D. Davis, Peter Grimison, on behalf of ANZUP +16 moredoaj +1 more sourceSalvage robot-assisted radical prostatectomy following focal ablation with irreversible electroporation: feasibility, oncological and functional outcomes
BMC Urology, 2022 Background To report the feasibility, oncological and functional outcomes of salvage robot-assisted radical prostatectomy (sRARP) for recurrent prostate cancer (PCa) after irreversible electroporation (IRE).Alexandar Blazevski, William Gondoputro, Matthijs J. Scheltema, Amer Amin, Bart Geboers, Daniela Barreto, Anne-Maree Haynes, Ron Shnier, Warick Delprado, Shikha Agrawal, James E. Thompson, Phillip D. Stricker +11 moredoaj +1 more sourceWNT signalling in prostate cancer [PDF]
, 2017 Genome sequencing and gene expression analyses of prostate tumours have highlighted the potential importance of genetic and epigenetic changes observed in WNT signalling pathway components in prostate tumours-particularly in the development of castration-A Ghoshal, A Gurney, A Jimeno, A Klaus, A Mallinger, A Mikels, A Säfholm, A Säfholm, AB El-Khoueiry, AC Vidal, AD,MR Kohn, AH Nile, AL Giraudet, AS Khaja, AS Perry, ASS Khaja, B Bilir, B Chen, B Madan, B Madan, BJ Feldman, BT MacDonald, C Fukukawa, C Lin, C Liu, C Liu, C Logan, C Niehrs, CL Chen, CM Cruciat, CS Grasso, CY Janda, D Grandy, D Robinson, D Zheng, DS Yee, DT Miyamoto, E Lee, E Lee, E Sandsmark, EE Storm, F Janku, F Ma, FC Gonsalves, G Chen, G O'Hurley, G Schulte, G Wang, GT Lee, H Beltran, H Clevers, H Hanaki, H Kimura, H Kumon, H Kumon, H Peradziryi, H Yamamoto, H Zhu, H-X Hao, HW Park, HX Hao, I Bisson, J Chinison, J Green, J Hao, J Liu, J Veeck, J Weischenfeldt, J-H Geng, JC Brase, JC Francis, JN Anastas, JP Dijksterhuis, JR Packer, K Ahmed, K Shojima, KC Valkenburg, KD Proffitt, KE Livermore, KH Emami, L Azzolin, L Fang, L Wu, L Zheng, LE Pascal, M Bordonaro, M Cojoc, M de la Roche, M Kahn, M Mancini, M Mazon, M Volante, M Yang, MD Shultz, MT Veeman, N Borcherding, N Li, N Takebe, NK Thudi, NN Yokoyama, O Dakhova, P Bovolenta, P García-Tobilla, P Le, P Polakis, P Rajan, P Uysal-Onganer, P Uysal-Onganer, PA Watson, R Eferl, R Kolb, R Siegel, R van Amerongen, R van Amerongen, RE O'Cearbhaill, RM Kypta, Robert Kypta, S Gupta, S Josson, S Martinez, S Perner, S Piccolo, S Takahashi, S Terry, S Thiele, S Thiele, S Zhang, S-P Huang, SA Tomlins, SH Lee, SJ Cooper, SJ Hotte, SJ Jung, SP Acebron, SP Acebron, T Chandrasekar, T Haikarainen, T Karantanos, T Malinauskas, T Phesse, TD Rachner, TM Bauman, TS Gujral, V Teneggi, Virginia Murillo-Garzón, W Lu, W Lu, W Tian, W Wang, X Chen, X Jiang, X Li, X Varelas, Y Eun-Jin, Y Kawano, Y Komiya, Y Li, Y Sun, Y Sun, Y Xie, Y Yang, Y Zhou, Y Zong, Z Debebe, Z Steinhart, ZG Li, ZJ Debruine +166 morecore +2 more sourcesA generalizable machine learning framework for classifying DNA repair defects using ctDNA exomes
npj Precision Oncology, 2023 Specific classes of DNA damage repair (DDR) defect can drive sensitivity to emerging therapies for metastatic prostate cancer. However, biomarker approaches based on DDR gene sequencing do not accurately predict DDR deficiency or treatment benefit ...Elie J. Ritch, Cameron Herberts, Evan W. Warner, Sarah W. S. Ng, Edmond M. Kwan, Jack V. W. Bacon, Cecily Q. Bernales, Elena Schönlau, Nicolette M. Fonseca, Veda N. Giri, Corinne Maurice-Dror, Gillian Vandekerkhove, Steven J. M. Jones, Kim N. Chi, Alexander W. Wyatt +14 moredoaj +1 more source
